For Investors

Corporate Profile
AVEO Oncology is a cancer therapeutics company committed to discovering, developing and commercializing targeted therapies to impact patients’ lives. AVEO’s proprietary Human Response Platform™ provides the company unique insights into cancer biology and is being leveraged in the discovery and clinical development of its cancer therapeutics.
Stock Quote
AVEO (Common Stock)
ExchangeNASDAQ (US Dollar)
Price$2.90
Change (%) Stock is Up 0.01 (0.35%)
Volume1,256,297
Data as of 05/21/13 4:00 p.m. ET
Minimum 20 minute delay
Refresh quote
Recent Press Releases 
DateTitle 
05/15/13AVEO and Astellas Announce Presentations of Tivozanib Clinical Data at 2013 American Society of Clinical Oncology Annual Meeting
CAMBRIDGE, Mass. & TOKYO--(BUSINESS WIRE)--May. 15, 2013-- AVEO Oncology (NASDAQ: AVEO) and Astellas Pharma Inc. (TSE: 4503) today announced that additional data from the Phase 3 TIVO-1 trial (TIvozanib Versus sOrafenib in 1st line advanced RCC) of investigational agent tivozanib in patients with advanced renal cell carcinoma (RCC) will be presented at the 2013 Annual Meeting of the American Society of Clinical Oncology (ASCO) taking place in ... 
Printer Friendly Version
05/02/13AVEO and Astellas Report FDA Oncologic Drug Advisory Committee Votes Tivozanib Application Did Not Demonstrate Favorable Benefit-to-Risk Evaluation in Treatment of Advanced Renal Cell Carcinoma
CAMBRIDGE, Mass. & TOKYO--(BUSINESS WIRE)--May. 2, 2013-- AVEO Oncology (NASDAQ: AVEO) and Astellas Pharma Inc. (TSE: 4503) today reported that the U.S. Food and Drug Administration’s (FDA) Oncologic Drugs Advisory Committee (ODAC) voted that the application for investigational agent tivozanib did not demonstrate a favorable benefit-to-risk evaluation for the treatment of advanced renal cell carcinoma (RCC) in an adequate and well-controlled trial (1... 
Printer Friendly Version
05/02/13Trading of AVEO Common Stock Halted
FDA Advisory Committee To Review Tivozanib for the Treatment of Advanced Renal Cell Carcinoma AVEO Conference Call Today at 4:30 p.m. ET CAMBRIDGE, Mass.--(BUSINESS WIRE)--May. 2, 2013-- AVEO Oncology (NASDAQ: AVEO) today announced that NASDAQ halted trading of AVEO common stock this morning, May 2, 2013. The U.S. Food and Drug Administration’s (FDA) Oncologic Drugs Advisory Committee (ODAC) meets today to discuss the New Drug ... 
Printer Friendly Version
More Press Releases >>
Upcoming Events 
There are currently no events scheduled.
More Events >>
Presentations 
Date
02/16/13
ASCO GU 2013 Tivozanib TIVO-1 Hypoxia Signature ccRCC - Abstract 361, Robinson
02/16/13
ASCO GU 2013 Tivozanib TIVO-1 Overall Survival - Abstract 350, Motzer
02/16/13
ASCO GU 2013 Tivozanib TIVO-1 QoL - Abstract 355, Cella
02/16/13
ASCO GU 2013 Tivozanib TIVO-1 Subgroups - Abstract 354, Hutson
02/16/13
ASCO GU 2013 Tivozanib Study 902 Efficacy Safety - Abstract 364, Motzer
More Presentations >>

Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.